Navigation Links
New Data: Cholesterol Management Analysis of Upsher-Smith's Slo-Niacin(R) Tablets in Combination with Lipitor(R)
Date:11/16/2009

MAPLE GROVE, Minn., Nov. 16 /PRNewswire/ -- Results of the SLIM Study ("Slo-Niacin® and Atorvastatin Treatment of Lipoproteins and Inflammatory Markers in Combined Hyperlipidemia") were recently published in the Journal of Clinical Lipidology. The objective was to study the lipid and anti-inflammatory effects of Slo-Niacin® 1.5 g/day and Lipitor (atorvastatin calcium) 10 mg/day, given alone and then together in persons with features of combined hyperlipidemia, high triglycerides, low high-density lipoproteins (HDL - "good cholesterol") and above average low-density lipoproteins (LDL - "bad cholesterol"). The result of the combination therapy was a marked decrease in triglycerides and LDL and a significant increase in HDL.1

"The efficacy of controlled-release Slo-Niacin® has never been studied with Lipitor," explained Dr. Robert Knopp, main author of the SLIM Study, professor of medicine at Harborview Medical Center and director of the Northwest Lipid Research Clinic. "The findings of the SLIM Study provide further foundation to the 20 years of experience with Slo-Niacin®."

Heart disease and stroke develop when elevated levels of LDL circulate in the blood and build up in the walls of the arteries that feed the heart and brain. Elevated triglycerides further this process. The result is plaque, a thick, hard deposit that narrows arteries and makes them less flexible. This condition is known as atherosclerosis. HDL, on the other hand, protects the blood vessels by carrying cholesterol away from the arteries and back to the liver, where it is passed from the body.2

About the study

In this trial, forty-two men and women ages 21 to 75 years with LDL levels greater than 130 mg/dL and HDL less than 45 mg/dL (women less than 55 mg/dL) were randomized to three months of Lipitor 10 mg/day or Slo-Niacin® titrated to 1.5 g/day. The alternate drug was then added in the next three month segment. Lipid profiles and liver enzymes were measured monthly. Additionally, a questionnaire regarding flushing was completed at each visit. Thirty-six participants finished the study.1

Monotherapy with Slo-Niacin® decreased median triglyceride levels 15 percent, mean LDL 12 percent and increased HDL 8 percent. Lipitor decreased median triglyceride levels 26 percent, mean LDL 36 percent and increased HDL 6 percent. Combined therapy decreased median triglycerides 33 percent, mean LDL 43 percent and increased HDL 10 percent.

Flushing symptoms were described as almost always tolerable. Only three subjects discontinued the study for niacin-related complaints and there was no indication of hepatotoxicity. Although not seen in this study, all niacin products carry the potential for liver function test elevations or hepatotoxicity, so monitoring is key.1

In summary, Slo-Niacin® was well-tolerated alone and in combination with Lipitor and benefitted all lipoprotein levels (HDL, LDL, and trigylcerides), as expected of niacin treatment.

About Slo-Niacin®

Slo-Niacin® Tablets (polygel® controlled-release niacin) are a niacin dietary supplement that have been trusted by healthcare professionals since 1988. Clinical trials have demonstrated that when dosed and monitored appropriately, Slo-Niacin® is complementary to statin therapy for cholesterol management, as demonstrated in the SLIM Study.1, 4

Slo-Niacin® is economical and often costs less than an insurance copayment. It is widely available at pharmacies and other retailers without a prescription as a dietary supplement. Slo-Niacin is available in three dosage strengths (250 mg, 500 mg and 750 mg) for individual dosing.3

Because Slo-Niacin® is a dietary supplement it is not intended to diagnose, treat, cure or prevent any disease. Patients taking more than 500 mg niacin daily should only do so under the advice and monitoring of a physician. Niacin may cause temporary flushing, particularly when beginning, increasing dosage or changing to other forms of niacin. Case reports of myopathy have been documented with the use of HMG-CoA reductase inhibitors in combination with lipid-altering doses of niacin therapy ( >/= 1 g niacin/day). Abnormal liver function tests have been reported in persons taking daily doses of 500 mg or more of niacin.

For more information contact a healthcare professional, call 1-800-654-2299 or visit www.slo-niacin.com.

About Upsher-Smith Laboratories, Inc.

Upsher-Smith Laboratories, Inc. is a rapidly growing pharmaceutical company that manufactures and markets both prescription and consumer products. Privately held since 1919, the company strives to recognize the unmet healthcare needs of our customers. Over the last 20 years that Upsher-Smith has been manufacturing Slo-Niacin®, more than 9.3 million bottles have been sold. Upsher-Smith prides itself in providing safe, effective, and economical therapies to the ever-challenged healthcare environment. For additional information about Upsher-Smith, visit www.upsher-smith.com.

References: 1. Knopp, R., Retzlaff, B., Fish, B., Dowdy, A., Twaddell, B., Nguyen, T., & Paramsothy, P. "The SLIM study: Slo-Niacin® and Atorvastatin Treatment of Lipoproteins and Inflammatory Markers in Combined Hyperlipidemia." Journal of Clinical Lipidology, 3(3), 167-178 (May 2009). 2. American Heart Association, http://www.americanheart.org/presenter.jhtml?identifier=180, July 14, 2009. 3. Slo-Niacin website, http://www.slo-niacin.com/, July 14, 2009. 4. Brown BG et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med. 2001;345:1583-92.

Lipitor is a registered trademark of Pfizer Inc.

These statements have not been evaluated by the U.S. Food and Drug Administration.

SOURCE Upsher-Smith Laboratories, Inc.


'/>"/>
SOURCE Upsher-Smith Laboratories, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Researchers at Cleveland Clinic Identify Site of Dysfunction in HDL, Carrier of Good Cholesterol
2. Synvista Collaboration Demonstrates in Preclinical Studies the Mechanism for Defective Cholesterol Transport in Patients with Diabetes
3. Isis Reports New Data for Mipomersen in Routine High Cholesterol Patients and Provides Cumulative Safety Summary
4. New Study Shows LEVITRA Successfully Treats Erectile Dysfunction (ED) in Men with Dyslipidemia, Including High Cholesterol
5. Recent Findings from the Framingham Offspring Study Show Low Numbers of LDL Particles (LDL-P) by NMR are Associated With Fewer Heart Disease Related Events than Equivalently Low Levels of LDL Cholesterol (LDL-C).(1)
6. People With Diabetes May Have All-Natural Citrus Supplement To Help Lower Blood Glucose and Cholesterol Levels
7. Blueberry-Supplemented Diet Shows Promise in Lowering Cholesterol in Animal Trials
8. Fish Oil and Red Yeast Rice Studied for Lowering Blood Cholesterol
9. VAP Cholesterol Test Helps Reveal Association Between Adiponectin Levels and Atherosclerosis
10. Leading Cardiologist Joins Ontario Research Firm to Conduct New Clinical Trial on the Effect of Pantethine on Cholesterol Levels
11. Colesevelam HCl Lowered LDL Cholesterol in Pediatric Patients With Heterozygous Familial Hypercholesterolemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... LEXINGTON, Mass. , June 24, 2016   ... specialty pharmaceutical company developing innovative inhaled drugs, announced today ... when Russell Investments reconstituted its comprehensive set ... 2016. "This is an important milestone for ... "It will increase shareholder awareness of our progress in ...
(Date:6/23/2016)... Research and Markets has announced the addition of the ... report to their offering. ... failure, it replaces the function of kidneys by removing the ... the treatment helps to keep the patient body,s electrolytes such ... Increasing number of ESRD patients & substantial healthcare expenditure on ...
(Date:6/23/2016)... , June 23, 2016 Roche (SIX: ... 510(k) clearance for its Elecsys BRAHMS PCT (procalcitonin) assay ... sepsis or septic shock. With this clearance, Roche is ... a fully integrated solution for sepsis risk assessment and ... with bacterial infection and PCT levels in blood can ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand ... project," said Christina Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s ... within Final Cut Pro X . Simply select a ProHand generator and drag ...
(Date:6/25/2016)... Oklahoma (PRWEB) , ... June 25, 2016 , ... ... both athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures ... Oklahoma City area —Johnson is one of the first doctors to perform the ...
(Date:6/24/2016)... ... 24, 2016 , ... A recent article published June 14 on ... article goes on to state that individuals are now more comfortable seeking to undergo ... such as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills ...
(Date:6/24/2016)... ... ... a crisis. Her son James, eight, was out of control. Prone to extreme mood shifts ... upset him, he couldn’t control his emotions,” remembers Marcy. “If there was a knife ... and say he was going to kill them. If we were driving on the ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with ... Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a ...
Breaking Medicine News(10 mins):